Martin David Harp

The acquisition focuses on LayerBio's OcuRing-K technology, with plans to initiate the next clinical trial.

Steel and the Glaucoma Research Foundation have a relationship spanning over a decade.

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

PA5108 is a rod-shaped, biodegradable microimplant designed to significantly reduce IOP in patients with primary open-angle glaucoma consistently over 6 months.

AAVB-039 is the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4.

Survey reveals severe impact of Good Days underfunding on retina practices, with many patients experiencing vision loss due to delayed access to care.

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and commercialize NCX 470.

Dr. Nimesh A. Patel reveals key findings on pegcetacoplan and anti-VEGF treatments for geographic atrophy and neovascular AMD at ASRS 2025.

The planned acquisition of STAAR includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia with or without astigmatism.

Ophthalmology celebrates 50 years of groundbreaking innovations, highlighting anti-VEGF therapies, OCT imaging, and future advancements in eye care.

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA

4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

RTP-008 features sustained immunosuppressant delivery for long-term therapeutic effects.

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society of Retina Specialists.

Steven D. Ness, MD, discusses his research on vitamin D's role in reducing complications after retinal surgery at ASRS 2025.

At ASRS 2025, Andrew G Lee, MD, gave key insight into the world of a neuro-ophthalmologist and why and when a retina specialist should consult a neuro-ophthalmologist

Yasha S. Modi, MD, discusses promising results from the VERONA study on EYP-1901, a potential treatment for diabetic macular edema.